Table 1.
Clinical characteristics of the study population (N = 169).
| Variable | Median (interquartile range)/Number (%) |
|---|---|
| Age (years) | 58.0 (50.0–65.0) |
| Female (N) | 136 (80.5%) |
| Caucasian (N) | 157 (94.6%)a |
| Body mass index (kg/m2) | 26.1 (23.4–29.8) |
| Disease duration (years) | 13.0 (7.0–23.0) |
| Rheumatoid factor positive (N) | 104 (62.7%)† |
| DAS28-CRP4 | 2.6 (2.0–3.8) |
| BPI pain intensity | 3.0 (2.0–5.0) |
| Fatigue | 35.0 (15.0–65.0) |
| Current DMARD use (N) | 149 (88.2%) |
| Current biologic DMARD use (N) | 98 (58.0%) |
| Current synthetic DMARD use (N) | 108 (63.9%) |
a
Percentages of Caucasian and rheumatoid factor positive participants are derived from a denominator of 166, due to missing data in these two categories.
b
DAS28-CRP = Disease Activity Score in 28 Joints – C-Reactive Protein, BPI = Brief Pain Inventory, DMARD = disease-modifying antirheumatic drug.